摘要
Epidemiological data indicate that gastric cancer(GC)remains highly prevalent in the world,although its global incidence is declining[1].It is the third leading cause of cancer death and a significant health burden in China[2-4].At the time of diagnosis,around 50%of GC cases are already locally advanced or metastatic[5,6]and can no longer be considered for curative surgical treatment[7].The prognosis for these patients is poor[4].Previous studies efforts have mainly focused on the improvements in chemotherapy and targeted therapy of advanced GC.So far,scientists have only found a few reagents that have shown to be effective against GC.However,the survival of GC patients treated with these reagents is marginal[8].Therefore,novel therapeutic approaches to treat GC are urgently required.
作者简介
Correspondence:Haibo Qiu,Email:qiuhb@sysucc.org.cn。ORCID:https://orcid.org/0000-0001-9360-6682。
